Gilead Sciences | GILD - Market Capitalization


Gilead Sciences reported $158.6B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 384.69B 19.14B Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
ALKERMES USD 5.88B 1.26B Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Coherus Biosciences USD 172M 19M Dec/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Gilead Sciences USD 172.99B 20.71B Mar/2026
GlaxoSmithKline GBP 83.8B 9.44B Mar/2026
Incyte USD 18.73B 660M Mar/2026
J&J USD 579.15B 78.91B Mar/2026
Merck USD 297.1B 35.84B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Novartis USD 307.76B 15.54B Mar/2026
Pfizer USD 153.81B 12.24B Mar/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Sanofi EUR 100.27B 605.48M Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
United Therapeutics USD 25.19B 4.21B Mar/2026
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026